Netscientific Share Discussion Threads

[dave4545] 04/8/2020 13:37

20p is £16 million

PDS is worth on a good run £5 mil at best

So are the other investments worth £11 million

Lets have some logic instead of one line ramps ?

[dave4545] 04/8/2020 13:35

But why should it be trading nearer the 20p mark

Show me why ???

[bowssbyjuhelm] 04/8/2020 13:30

Anyways all the best mate. No point arguing with you. If you're a genuine investor. This should be trading around the 20p mark by end of this week. But would depend on a number of factors as always. Dyor gla

[dave4545] 04/8/2020 13:27

Nothing wrong with PDS at all...looks great

But NSCI stake in it is only worth around £4-5 million...

[bmwman3] 04/8/2020 13:26

Just putting it out there to show people there is some substance behind this albeit from a few days ago! Regards!

[tidy 2] 04/8/2020 13:23

Yep Preclinical DataToo late if you are spiked now. Wait for the next ramp up.

[rk23] 04/8/2020 13:23

Filter buttons being overused today.....

[bmwman3] 04/8/2020 13:20

Previous RNS 27th July PDS Biotechnology Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccinationNetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) today announced preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203). PDS0203 pairs the Versamune® platform with a recombinant protein recognized by the human immune system that is derived from the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus that causes COVID-19. The protein included in PDS0203 encompasses SARS-CoV-2 sections that induce an antibody response, as well as sections that are recognized by CD8 and CD4 T-cells. PDS Biotech has generated robust preclinical data confirming that PDS0203 elicits induction of highly active and potent virus-specific CD8 killer and CD4 helper T-cells within 14 days of treatment. Importantly, the study also demonstrated induction of the long-lasting virus-specific memory T-cells necessary for longer term protection. PDS0203 demonstrated a 30-45 fold increase in COVID-19 specific T-cells by Day 14 when compared to the vaccine without Versamune®. These preclinical studies also confirmed induction of strong anti-SARS-CoV-2 neutralizing antibodies within 14 days, with a 20-25-fold increase when compared to the vaccine without Versamune®. Lastly, these preclinical studies showed a further substantial increase in neutralizing antibody levels continuing more than 30 days after vaccination. PDS Biotech plans to submit details of the preclinical studies to a peer reviewed scientific journal.As previously announced, the Company has also initiated preclinical development of Versamune®-CoV-2FC (PDS0204), a COVID-19 vaccine candidate being developed in partnership with Brazil-based Farmacore Biotechnology, which combines the immune-activating Versamune® platform with a Farmacore-developed SARS-CoV-2 recombinant fusion protein.NetScientific holds 7.18% of PDS' undiluted share capital.Dr. Ilian Iliev, Chief Executive Office of the Company said: "We are delighted with the excellent progress made by PDS Biotechnology since the investment anchored by NetScientific earlier this year, and that it is contributing to the global efforts towards the COVID-19 pandemic."The full details of the announcement are set out below and can be found he re: https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/56-2020-news/406-iotechnnouncesreclinicalatafor0203ael20200727 # # #PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccinationFLORHAM PARK, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced preclinical data for its COVID-19 vaccine candidate, Versamune-CoV-2 (PDS0203). PDS0203 pairs the Versamune® platform with a recombinant protein recognized by the human immune system that is derived from the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus that causes COVID-19. The protein included in PDS0203 encompasses SARS-CoV-2 sections that induce an antibody response, as well as sections that are recognized by CD8 and CD4 T-cells. PDS Biotech has generated robust preclinical data confirming that PDS0203 elicits induction of highly active and potent virus-specific CD8 killer and CD4 helper T-cells within 14 days of treatment. Importantly, the study also demonstrated induction of the long-lasting virus-specific memory T-cells necessary for longer term protection. PDS0203 demonstrated a 30-45 fold increase in COVID-19 specific T-cells by Day 14 when compared to the vaccine without Versamune®. These preclinical studies also confirmed induction of strong anti-SARS-CoV-2 neutralizing antibodies within 14 days, with a 20-25-fold increase when compared to the vaccine without Versamune®. Lastly, these preclinical studies showed a further substantial increase in neutralizing antibody levels continuing more than 30 days after vaccination. PDS Biotech plans to submit details of the preclinical studies to a peer reviewed scientific journal."Recent COVID-19 research has highlighted the critical importance of developing vaccines capable of generating high levels of targeted CD8 and CD4 T-cells, in addition to neutralizing antibodies, to achieve durable protection against COVID-19 infection. Our preclinical data shows PDS0203's ability to rapidly induce both protective antibodies and long-lasting T-cells specific for COVID-19," commented Dr. Frank Bedu-Addo, CEO of PDS Biotech, "Due to the mechanism by which Versamune® activates a disease-specific immune response, our PDS0101 program demonstrated successful translation of T-cell induction and safety data from preclinical models to humans. We therefore believe that this encouraging PDS0203 preclinical data may similarly translate to humans. If so, then it may present unique potential to provide the breadth and level of immune responses necessary for a safe and effective vaccine with long-term protection against COVID-19."As previously announced, the Company has also initiated preclinical development of Versamune®-CoV-2FC (PDS0204), a COVID-19 vaccine candidate being developed in partnership with Brazil-based Farmacore Biotechnology, which combines the immune-activating Versamune® platform with a Farmacore-developed SARS-CoV-2 recombinant fusion protein.About the Versamune® technology platformThe Versamune® technology is based on proprietary immune activating lipids that uniquely activate an important immunological signaling pathway, called the Type 1 interferon signaling pathway, known to be important in the induction of both anti-viral and anti-tumor immune responses. It also promotes efficient access of the disease-specific immunologically recognized protein (antigen) into two important immunological pathways called the Class I and II MHC pathways, therefore enabling powerful induction and activation if CD8 (Killer) and CD4 (helper) T-cells that can recognize, kill and protect against the specific disease. The technology is protected by multiple international composition and application patents.About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.About PDS0203PDS0203 is a COVID-19 vaccine candidate that combines the utility of the Versamune® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein. The World Health Organization (WHO) declared the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread. Building immunity to the disease is the key to stopping its spread. A COVID-19 vaccine would train the immune system to recognize and destroy the virus without the vaccinated person getting sick.About PDS0204PDS0204 is a COVID-19 vaccine candidate that combines the utility of the Versamune® platform with a Farmacore-developed recombinant fusion protein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread. Building immunity to the disease is the key to stopping its spread. A COVID-19 vaccine would train the immune system to recognize and destroy the virus without the vaccinated person getting sick.

[saint in exile] 04/8/2020 13:18

Its the Dave and Dave show!

[investordave] 04/8/2020 13:14

The pump and dump merchants should be strung up from the nearest lamppost. Scumbags one and all.

[bowssbyjuhelm] 04/8/2020 13:06

Pretty sure I saw you turn up at Cadence minerals, COPL, CTEA... and plenty of others so please grow up. And don't paint me with the same brush. What on earth do you mean 'you lot' ?

[dave4545] 04/8/2020 13:00

"i've been holding for years"

lol

You lot just cannot help yourselves !

[amrishbhim] 04/8/2020 13:00

Sick andTwisted, not going to waste my time when you aroundNobody wants you now,

[saint in exile] 04/8/2020 12:55

Yep seen Davey boy on numerous pump expeditions..do these guys ever make any money?

[bowssbyjuhelm] 04/8/2020 12:53

Dave to be honest ive noticed your name along with others like Sharif1987 turn up on the boards of shares I've been holding for years, only when it spikes. So hard to tell which one of you are genuine. Maybe two sides of the same coin. Anyway, back to business please guys. Anyone else see this closing 100%+ today or is it just me?

[dave4545] 04/8/2020 12:49

amrish

You'll be chasing a loss in shares forever buying spikes all the time.

It's funny you keep turning up on them all but then afterwards claiming not to have
bought in.

You must think people are idiots.

Do not get impaled folks

[amrishbhim] 04/8/2020 12:48

SickOfYou MakeYour caseNot the selfish way.

[bmwman3] 04/8/2020 12:48

The nsci Vaccine along with the Oxford vaccine it the only other vaccine that gives antibodies and t-cells so expect fireworks.

[amrishbhim] 04/8/2020 12:47

I'm sick and tired of seeing him everyday thinkingHe knows it all

[amrishbhim] 04/8/2020 12:47

I know Dave his certainly

[amrishbhim] 04/8/2020 12:46

I blame you forYour lies and derampingShares you don't like or have spiked, ramping shares that's benefit you, you areA selfish man, don't blame others, who do you think you are. I will follow you everywhere andLet it know if you open your mouth with b/s